Domestic brokerage firm HDFC Securities has initiated coverage on several healthcare stocks. It sees a strong potential for value unlocking in these companies, which includes Apollo Hospitals Enterprise and Dr Lal Pathlabs. Here is a list of 5 healthcare stocks on which HDFC Securities initiated coverage:
IANS
2/6
Max Healthcare Institute | CMP: Rs 839
HDFC Securities initiated coverage on Max Healthcare Institute with an Add rating. The brokerage firm set a target price of Rs 900 on the stock, which shows an upside potential of 7% from the current market prices.”Its expansion plans for the next five years will drive the next leg of growth; this plan envisages the addition of ~800 beds in FY25 and 1,100 in FY26. Further, the recent acquisitions of operational hospitals, Sahara Hospital in Lucknow (250-bed capacity) and Alexis Hospital in Nagpur (200-bed capacity) are poised to support growth. Additionally, Max Lab, the company’s diagnostics business, is expected to witness robust scaling up in the coming years,” it said.
Agencies
3/6
Apollo Hospitals Enterprise | CMP: Rs 5,870
HDFC Securities initiated coverage on Apollo Hospitals Enterprise with a Buy rating. The brokerage firm set a target price of Rs 7,030 on the stock, which implies an upside potential of 20% from the current market prices.”We expect APHS to see 17/25% sales/EBITDA CAGRs over FY23-26E and margin improvement to ~14.8% in FY26. We initiate coverage with BUY rating and assign (1) EV/E of 26x to hospital, (2) EV/E of 16x to offline pharmacy, (3) EV/E of 23x to AHLL, and (4) 1x EV/ sales for Apollo 24/7 sales to arrive at SoTP of Rs 7,030 (blended 26x FY25E EV/E),” the brokerage firm said.
Agencies
4/6
Medplus Health Services | CMP: Rs 695
Domestic brokerage firm HDFC Securities initiated coverage on Medplus Health Services with a Buy rating. The brokerage firm set a target price of Rs 850 on the stock, which indicates an upside potential of 22% from the current market prices.The brokerage expects MEDPLUS’s growth to be driven by: (1) the addition of ~600-700 stores p.a. for deeper penetration in existing clusters to continue expansion in key cities/metros/Tier 1 and expansion in Tier 2 and beyond and the addition of new states; (2) leveraging the omnichannel presence; (3) increasing its private-label share; (4) scaling up its diagnostics business; and (5) the introduction of Medplus brand generics at 50-80% discounts.
Agencies
5/6
Dr Lal Pathlabs | CMP: Rs 2,586
HDFC Securities initiated coverage on Dr Lal Pathlabs with an Add rating. The brokerage firm set a target price of Rs 2,700 on the stock, which implies an upside potential of 4% from the current market prices.”DLPL’s remarkable trend in the past has slowed down due to increasing competition and price pressure; accordingly, we expect the company to see 11/15/25% sales/EBITDA/PAT CAGRs over FY23-26E. We see a gradual improvement in realization, an increasing share of speciality/Swasthfit, and cost controls to help margin sustain at ~27% in FY25-26,” the brokerage firm said.
6/6
Metropolis Healthcare | CMP: Rs 1,957
HDFC Securities initiated coverage on Metropolis Healthcare with an Add rating. The brokerage firm set a target price of Rs 2,010 on the stock, which shows an upside potential of 3% from the current market prices.”We expect METROHL to see 10/12/16% sales/EBITDA/PAT CAGRs over FY23-26E led by expansion, core business recovery, and price hikes (improvement in realization). Increasing share of specialized tests and wellness, lab infra maturity (current dilution of ~1.2%) and a slowdown in expansion may drive the margin to ~26.3% in FY26,” it said.
Denial of responsibility! Secular Times is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – seculartimes.com. The content will be deleted within 24 hours.
